Další formáty:
BibTeX
LaTeX
RIS
@proceedings{987354,
author = {Čoupková, Helena and Skřičková, Jana and Hejduk, Karel and Bortlíček, Zbyněk and Kadlec, Bohdan and Salajka, František and Pešek, Miloš and Kolek, Vítězslav and Koubkova, Leona and Sixtova, Dimka and Zatloukal, Petr and Roubec, Jaromír and Zemanová, Milada and Vyzula, Rostislav and Špelda, Stanislav},
booktitle = {2012 ASCO Annual Meeting},
language = {eng},
title = {Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic},
year = {2012}
}
TY - CONF
ID - 987354
AU - Čoupková, Helena - Skřičková, Jana - Hejduk, Karel - Bortlíček, Zbyněk - Kadlec, Bohdan - Salajka, František - Pešek, Miloš - Kolek, Vítězslav - Koubkova, Leona - Sixtova, Dimka - Zatloukal, Petr - Roubec, Jaromír - Zemanová, Milada - Vyzula, Rostislav - Špelda, Stanislav
PY - 2012
TI - Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic
N2 - Erlotinib is approved for NSCLC treatment in Czech Rep since 2005. This analysis was performed to analyze the profile of pts treated with erlotinib longer than 6 months. Methods: This retrospective analysis evaluates data from Czech Tarceva Registry of pts treated outside clinical trials. Survival (mOS, mPFS) was evaluated by the Kaplan-Meier method, survival comparison was performed by Log Rank test. Results: Up to October 2011, 430 out of 2121 pts with completed data in registry were treated with erlotinib for 6 months and longer. Median age 65 years, 54.4% men; 29.8% smokers, 37.9% former smokers, 32.3 % non-smokers; 77% pts ECOG PS 0-1. 74.7% stage IV pts, 21.4% stage IIIB. 43.5% adenoca, 31.9% squamous ca,11% non-specific NSCLC, 6% bronchioloalveolar ca. Erlobinib administered as 1st line treatment in 13% pts, 2L in 50.9%, 3L in 34.9%. Till October 2011, 322 pts (74.9%) finished the treatment, 108 pts (25.1%) still on erlotinib therapy. Treatment discontinued due to progression in 75% pts, death in 15%, toxicity in 3%. The entire group results (n=430): CR in 2.3%, PR in 17.7%, SD in 65.8%, PD in 2.6%. mPFS and mOS from erlotinib initiation 12.4 and 21.4 months respectively. mOS from diagnosis was 43.5 months. Statistical difference in mOS (from the erlotinib initiation) was observed between groups with PS ECOG 0-1 and PS 2-3, 22.0 vs 16.4 months (p=0.001), although there was no difference in both groups in mPFS (12.9 vs. 10.6 months). mPFS and mOS in pts with adenoca (n=187) from erlotinib initiation 14.4 and 23.7 months respectively. mOS from diagnosis was 45.6 months. mPFS and mOS in pts with squamous ca (n=137) from erlotinib initiation was 11.3 and 17.6 months respectively. mOS from diagnosis was 42.2 months. Conclusions: This analysis documented good activity of erlotinib in both adeno and squamous cell carcinoma. The difference in mOS and mPFS between both groups was statistically significant when measured from erlotinib initiation (mOS: p= 0.017, mPFS: p=0.022), however not statistically significant when measured from the date of diagnosis (p=0.361). Patients with PS 0-1 have statistically significantly greater mOS than patients with worse PS (p=0.001).
ER -
ČOUPKOVÁ, Helena, Jana SKŘIČKOVÁ, Karel HEJDUK, Zbyněk BORTLÍČEK, Bohdan KADLEC, František SALAJKA, Miloš PEŠEK, Vítězslav KOLEK, Leona KOUBKOVA, Dimka SIXTOVA, Petr ZATLOUKAL, Jaromír ROUBEC, Milada ZEMANOVÁ, Rostislav VYZULA a Stanislav ŠPELDA. Characteristics of advanced NSCLC patients with at least 6 months erlotinib treatment duration in Czech Republic. In \textit{2012 ASCO Annual Meeting}. 2012. ISSN~0732-183X.
|
